Bruce Roth

Medicine & Life Sciences

1. Germ Cell and Embryonal Neoplasms 100%
2. Prostatic Neoplasms 88%
3. Paclitaxel 77%
4. Drug Therapy 75%
5. Urothelium 74%
6. Cisplatin 63%
7. Carcinoma 63%
8. Ifosfamide 60%
9. Vinblastine 59%
10. Urinary Bladder Neoplasms 59%
11. Testicular Neoplasms 50%
12. Survival 48%
13. Neoplasms 39%
14. Combination Drug Therapy 36%
15. Prostate-Specific Antigen 36%
16. Estramustine 36%
17. gemcitabine 32%
18. Therapeutics 32%
19. Hormones 29%
20. Everolimus 29%
21. gallium nitrate 28%
22. cabozantinib 28%
23. Docetaxel 27%
24. Etoposide 27%
25. Transitional Cell Carcinoma 25%
26. Renal Cell Carcinoma 25%
27. Doxorubicin 25%
28. Lymph Node Excision 24%
29. Androgens 23%
30. Salvage Therapy 21%
31. Carboplatin 20%
32. Methotrexate 18%
33. Castration 18%
34. Vascular Endothelial Growth Factor Receptor 16%
35. Pemetrexed 15%
36. Radiotherapy 15%
37. piritrexim 15%
38. E 3800 15%
39. Progression-Free Survival 14%
40. Leukemia, Megakaryoblastic, Acute 14%
41. Protein-Tyrosine Kinases 14%
42. Guidelines 14%
43. Medical Oncology 13%
44. Maximum Tolerated Dose 13%
45. Pharmacokinetics 13%
46. Small Cell Lung Carcinoma 13%
47. Mediastinal Neoplasms 13%
48. Interferons 12%
49. Megakaryocytes 12%
50. Prostate 12%